Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements

Louis Drevon,[1,2,3] Nabih Maslah,[1,2,3] Juliette Soret-Dulphy,[2,4] Christine Dosquet,[1,2,3] Odno Ravdan,[1] Laetitia Vercellino,[5] Célia Belkhodja,[1,2,3] Nathalie Parquet,[6] Anne C. Brignier,[6] Marie-Hélène Schlageter,[1,2,3] Bruno Cassinat,[1,2,3] Jean-Jacques Kiladjian,[2,3,4] Christine Chomienne[1,2,3] and Stéphane Giraudier[1,2,3]

[1]APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, F-75010 Paris; [2]France Intergroupe des Syndromes Myéloprolifératifs (FIM); [3]Université de Paris, U1131 INSERM, IRSL, F-75010 Paris; [4]APHP, Centre d'Investigations Cliniques, Hôpital Saint-Louis, F-75010 Paris; [5]APHP, Service de Médecine Nucléaire, Hôpital Saint-Louis, F-75010 Paris and [6]APHP, Service d'Aphérèse Thérapeutique, Hôpital Saint-Louis, F-75010 Paris, France

Correspondence: STEPHANE GIRAUDIER - stephane.giraudier@aphp.fr

doi:10.3324/haematol.2020.249409

RCM measurement
n = 2858

« Anemic patients »
Hb < 119 g/L (F) or 129 g/L (M)
n = 63

Non anemic and non polycythemic patients
Hb 120-160 g/L (F) or 130-165 g/L (M)

« Polycythemic patients »
Hb > 160 g/L (F) or 165 g/L (M)
n = 1815

« Control patients »
Hct ≤ 48% (F) or ≤ 49% (M), MCV 80 - 100 fL, RCM ≤ +25%, JAK2 V617F neg, no splenomegaly, WBC 4 - 10. 10^9/L, platelets 150 - 450.10^9/L
n = 97

« Excluded »
Hct > 48% (F) or > 49% (M), MCV < 80 or > 100 fL, RCM > +25%, JAK2 V617F pos, splenomegaly, WBC < 4 or > 10. 10^9/L, or platelets < 150 or > 450.10^9/L
n = 883

Supplementary figure 1. Diagnostic Chart.
The number of patients concerned in each step of the chart is noted next to each item (n).